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Abstract 
 
Prurigo is defined by the presence of chronic pruritus and multiple localized or generalized pruriginous 
lesions. The aim of this study was to use an epidemiological approach to assess the psychological 
burden of patients with prurigo in European countries. In this multicentre European study, 3635 
general dermatology outpatients[AF1] and 1959 controls were included. Socio-demographic data and 
answers to questionnaires (regarding quality of life, general health, anxiety and depression and suicidal 
ideation) were collected. There were 27 patients with prurigo; of these, 63% were men, and the mean 
age was 58.6 years old. Among patients with prurigo, 37.1[AF2]% suffered from anxiety and 29.6% from 
depression. Nineteen percent[AF3] of patients reported suicidal ideation, and for 80% of these patients, 
suicidal ideation concerned their skin disease. These frequencies were higher than in the 10 
commonest dermatological diseases (including psoriasis, atopic dermatitis and leg ulcers for example). 
The impact on quality of life was severe, with a mean DLQI of 12.4, with an extreme impact on quality 
of life for 23% of patients and a very large impact for 27% of patients. The psychological comorbidities 
of prurigo are severe[AF4], greater than those of other dermatoses, and their impact on quality of life 
was significant. Thus, it is important to study this disease and to find new treatments.   
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Introduction 
 
Prurigo occurs along with chronic pruritus and presents with symmetrically distributed papules, 
nodules and/or plaques (1). This disorder is characterized by intense pruritus as the dominant 
symptom (2,3). The skin between the nodules is usually normal. The term prurigo has been used for 
many decades without a clear definition. Recently, the European experts of the Task Force Pruritus of 
the European Academy of Dermatology and Venereology achieved a consensus regarding the 
definition, classification and terminology of prurigo (4). Prurigo is[AF5] a distinct disease that is defined 
by the presence of chronic pruritus and multiple localized or generalized pruriginous lesions (4). 
Prurigo is related to a neuronal sensitization to itch and development of an itch-scratch cycle. Prurigo 
can be associated with pruritus of dermatological, systemic, neurologic, psychiatric/psychosomatic, 
multifactorial or undetermined origin. It is still a matter of controversy whether prurigo represents a 
separate entity or is a reaction pattern due to the vicious circle of repeated itching and scratching. 
Little is known about the epidemiology and comorbidities associated with prurigo, particularly 
psychiatric disorders, such as anxiety and depression.  
The aim of this study was to gather[AF6] data about prurigo from a large multicentre European study 
of general dermatology outpatients and to assess the psychological burden of these patients.   
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Patients and methods 
 
Participants  
 
A multicentre observational cross-sectional study was conducted in 13 European countries (5).  
Consecutive dermatology outpatients were invited to participate on random days. The inclusion 
criteria were age > 18 years, understanding the local language and not suffering from severe mental 
disease. Each centre recruited 250 patients; then, another 25 patients, increasing the number of 
participants. In total, 5442 individuals agreed to participate (79.9% of those invited). Of the initial 4026 
patients, 16 were excluded: nine were too young and seven had missing data. A control group of 
healthy workers was invited to participate. Of the initial 1416 controls, 57 were excluded because they 
had a skin disease. Data were therefore used from 4010 patients and 1359 controls. Each patient was 
clinically examined by the dermatologist, who recorded the diagnosis, its severity, and comorbidities, 
including cardiovascular disease, chronic respiratory disease, diabetes mellitus, rheumatological 
disease and other conditions such as cancer. In our study, we identified cases of prurigo and compared 
their data to control patients and patients with other dermatological diseases. 
 
 
Questionnaires  
 
Each participant was asked to complete a two part document. The first part contained questions about 
socio-demographic variables: sex, age, ethnicity, marital status, education and self-reported socio-
economic status. The second part contained several questionnaires:  
-The Dermatologic Life Quality Index (DLQI) (6) consists of ten questions about symptoms, 
embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close 
relationships, sex and treatment. Each question is scored from 0 to 3, giving a possible score range 
from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life).   
-The EuroQol 5 dimensions 3 levels (EQ-5D-3L) consists of 2 parts: the EQ-5D-3L descriptive system and 
the EQ Visual Analogue Scale (EQ VAS) (7). The EQ-5D-3L descriptive system comprises the following 5 
dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each 
dimension has 3 levels: no problems, some problems, and extreme problems. The EQ VAS records the 
ƌespoŶdeŶt’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled 
͞ďest imaginable health state͟ and ͞ǁoƌst imaginable health state͟.  
-The Hospital Anxiety and Depression Scale (HADS), a well-validated instrument that has good 
psychometric properties, has been used to assess the symptoms of anxiety disorders and depression 
in somatic, psychiatric, and primary care patients, as well as in the general population (8). The HADS 
includes seven items that assess anxiety and seven for depression, each with four possible answers. 
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For each dimension of anxiety and depression, a score from 0 to 7 is considered normal, from 8 to 10 
is considered a borderline case, and from 11 to 21 is considered a case in need of further examination 
or treatment. This instrument was used in the validated translations relevant to the study 
countries[AF7]. 
- To assess suiĐidal ideatioŶ, the iteŵ ͞Haǀe Ǉou eǀeƌ thought of ĐoŵŵittiŶg suiĐide?͟ ǁith possiďle 
answers of "yes" or "no" was included. AŶ additioŶal ƋuestioŶ ǁas giǀeŶ to the patieŶt gƌoup: ͞Haǀe 
Ǉou eǀeƌ thought of ĐoŵŵittiŶg suiĐide ďeĐause of Ǉouƌ skiŶ?͟ 
The deƌŵatologist aŶsǁeƌed tǁo ƋuestioŶs: ͞ Do Ǉou see depƌessiǀe sigŶs iŶ the patieŶt?͟ aŶd ͞ Do Ǉou 
see anxiety sigŶs iŶ the patieŶt?͟ ǁith the possiďle aŶsǁeƌs: ͞Ǉes͟ oƌ ͞Ŷo͟.  
 
 
 
Statistical analysis 
 
All data were analysed using Microsoft Office Excel.  The quantitative variables were described using 
the mean and standard deviation. The means of the two groups (prurigo patients and controls) were 
Đoŵpaƌed ǁith “tudeŶt’s T test[AF8]. The qualitative variables were described using the frequency and 
were compared between the two gƌoups ǁith a Chi sƋuaƌe test oƌ Fisheƌ’s eǆaĐt test iŶ the Đase of 
small sample sizes. For all statistical analyses, the type 1 error was set at 5%. Data of prurigo patients 
were also compared with data of the 10 more frequent dermatoses (psoriasis, non-melanoma skin 
cancer, infections skin, eczema, acne, nevi, atopic eczema, benign skin tumours, hand eczema, leg 
ulcers) for the HADS score or with all dermatoses for DLQI in a descriptive way. 
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Results 
The details of the participants’ characteristics have been previously published (5). In this study, we 
included 27 patients with prurigo. The socio-demographic characteristics and comorbidities of 
patients with prurigo and controls are presented in Table 1.  
 Patients with 
prurigo  
n=27 
Controls 
n=1359 
p-value 
Countries, No (%) 
   Belgium 
   Denmark 
   France 
   Germany 
   Hungary 
   Italy 
   Netherlands 
   Norway 
   Poland 
   Russia 
   Spain 
   Turkey 
   United Kingdom 
 
2 (7.4) 
3 (11.1) 
1 (3.7) 
2 (7.4) 
0 
5 (18.5) 
4 (14.8) 
6 (22.2) 
2 (7.4) 
0 
0 
1 (3.7) 
1 (3.7) 
 
131 (9.6) 
122 (9.0) 
20 (1.5) 
133 (9.8) 
134 (9.9) 
46 (3.4) 
0 
218 (16.0) 
125 (9.2) 
120 (8.8) 
116 (8.5) 
109 (8.0) 
85 (6.3) 
 
Age, years (MD=1/18) 
   Range 
   Mean +/- SD 
 
28-84 
58.6 +/-15.1 
 
18-89 
41.1 +/-13.6 
 
 
<0.001 
Sex, No (%) (MD=0/3) 
   Female 
 
10 (37.0) 
 
903 (66.6) 
 
0.001 
Marital status, No (%) (MD=5/3) 
   Single 
   Married/partner 
   Separated/divorced 
   Widowed 
 
2 (9.1) 
15 (68.2) 
2 (9.1) 
3 (13.6) 
 
362 (26.7) 
840 (62.0) 
119 (8.8) 
34 (2.5) 
 
 
0.017 
Educational level, No (%) (MD=0/8) 
   Low 
   Higher 
   University 
 
8 (29.6) 
18 (66.7) 
1 (3.7) 
 
375 (27.8) 
399 (29.5) 
577 (42.7) 
 
 
<0.001 
Stressful events during last 6 months, 
No (%) (MD=0 /13)     
 
10 (37.0) 
 
412 (30.6) 
 
0.47 
Symptoms of No (%) 
   Depression  (MD=4/7) 
   Anxiety (MD=4/9) 
 
5 (21.7)  
6 (26.1) 
 
182 (13.5) 
356 (26.4) 
 
0.22 
0.98 
Comorbidities, No (%)  
   Heart disease (MD=2/303) 
   Respiratory  (MD=5/307) 
   Diabetes, (MD=2/305) 
   Rheumatological disease (MD=3/305) 
 
5 (20.0) 
3 (13.1) 
4 (16.0) 
1 (4.2) 
 
78 (7.4) 
47 (4.5) 
24 (2.3) 
48 (4.6) 
 
0.037 
0.078 
0.003 
1 
 Table 1. Socio-demographic characteristics and comorbidities of patients with prurigo and controls 
MD: missing data 
8 
 
The severity of prurigo was evaluated by the doctor as slight in 20% of patients, mild in 50% and severe 
in 30%. Only 53.8% of patients claimed to know their diagnosis. Symptoms were present for more than 
oŶe ŵoŶth iŶ 9ϲ.Ϯ% of Đases. To the ƋuestioŶ, ͞ ǁhat is Ǉouƌ leǀel of ĐoŶĐeƌŶ aďout Ǉouƌ skiŶ disease?͟, 
55.6% of patients aŶsǁeƌed ͞ǀeƌǇ ŵuĐh͟, ϯϳ.Ϭ% ͞ŵiddle͟ aŶd ϳ.ϰ% ͞little͟. PatieŶts ƌepoƌted a flaƌe-
up of their skin disease every day in 57.7% of cases, every week in 11.5%, every month in 11.5% and 
several times a year in 19.2%. Approximately 50.0% of prurigo lesions were located on the torso, 46.1% 
on the hands, 26.9% on the scalp and 23.1% on the face [AF9] . Approximately 88.5% of patients 
presented with pruritus at the time of examination. The mean itch intensity was 6.6 +/- 3.1 and ranged 
from 0 to 10. 
Data about anxiety, depression and suicidal ideation for patients with prurigo and controls are 
presented in Table 2. 
 Patients with 
prurigo 
n=27 
Controls 
n=1359 
p-value 
HADS anxiety 
   Range  
   Mean +/- SD 
   ≥ ϭϭ ;aŶǆietǇ ĐliŶical case)   
 
0-17 
8.3 +/- 4.8 
10 (37.1%) 
 
0-18 
4.7+/-3.5 
150 (11.1%) 
 
 
 
<0.001 
HADS depression 
   Range  
   Mean + /- SD 
      ≥ ϭϭ ;depƌessioŶ ĐliŶiĐal ĐaseͿ 
 
1-16 
7.6 +/- 4.1 
8 (29.6%) 
 
0-16 
4.3+/-3.2 
58 (4.3%) 
 
 
 
<0.001 
Suicidal ideation (MD=1) 
   Suicidal ideation  
   Suicidal ideation concerning the skin 
disease (among those with suicidal 
ideation) 
Suicidal ideation concerning the skin 
disease    (in the whole sample) 
 
5 (19.2%) 
4 (80.0%) 
 
4 (15.4%) 
 
 
88 (8.3%) 
N.A 
 
N.A 
 
0.03 
Table 2. Anxiety, depression and suicidal ideation in patients with prurigo and controls 
MD: missing data, N.A: not applicable 
AppƌoǆiŵatelǇ ϯϳ.ϭ% of pƌuƌigo patieŶts suffeƌed fƌoŵ aŶǆietǇ diagŶosed ǁith a HAD“ aŶǆietǇ≥ ϭϭ, 
which was significantly higher[AF10][AF11] than that of the controls and more than that for the 10 more 
common dermatological conditions of the cohort of patients: 22.7% of patients with psoriasis, 21.0% 
of patients with hand eczema, 17.6% of patients with atopic eczema, 17.5% of patients with leg ulcers 
suffered from anxiety. 
In the same manner, 29.6% of prurigo patients suffered from depression diagnosed with a HADS 
depƌessioŶ≥ ϭϭ, ǁhiĐh ǁas sigŶifiĐaŶtlǇ greater[AF12] than that of the controls (4.3%) and higher than 
that of the 10 other more common dermatological conditions of the cohort of patients: 24.3% of 
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patients with leg ulcers, 15.1% of patients with hand eczema, 13.8% of patients with psoriasis and 
10.1% of patients with atopic eczema suffered from depression.  
Finally, 19.2% of prurigo patients reported past or present suicidal ideation, which was significantly 
higher[AF13] than that of controls (8.3%) and more than that of the 10 more common dermatological 
conditions of the cohort: in fact, 17.8% of patients with leg ulcers, 17.3% of patients with psoriasis, 
15.4% of patients with atopic eczema and 14.2% of patients with hand eczema reported suicidal 
ideation.  
We analysed the concordance of the diagnosis of anxiety and depression between the dermatologist 
and that suggested by the HADS questionnaire in the 27 prurigo patients: it was 75.0% when there was 
no depression and 78.6% when there was no anxiety. The true positive value was 50.0% for anxiety 
and 20.0% for depression, and the false negative value was 66.7% for depression and 64.7% for anxiety. 
The dermatologists underestimated depression and anxiety in 26.1% of consultations. On the other 
hand, dermatologists overestimated depression and anxiety in 17.4% and 13.0%, respectively, of 
consultations. 
The mean DLQI was 12.4 +/- 8.6, with a range from 0 to 30. The distribution of the score categories of 
DLQI is presented in Figure 1. Compared to the 25 other dermatoses, prurigo had a large impact on 
quality of life, the same as hidradenitis suppurativa (DLQI=12.4) and greater than that of atopic 
dermatitis (DLQI=11.4) and pruritus (11.2). The values for all of the other dermatoses were under 10.   
 
Figure 1: DLQI scores in patients with prurigo 
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The results of the EQ-5D-3L descriptive system are presented in Figure 2. The EQ VAS was 57.4 +/- 16.5. 
Among the dermatological diseases studied, prurigo had the third worst self-reported health, with a 
score of 57.4, behind leg ulcers (56.0) and hidradenitis suppurativa (56.9).  
 
 
 
Figure 2. Results of the 5 dimensions of the EQ-5D-3L descriptive system for patients with prurigo.  
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Discussion 
In our study, anxiety, depression and suicidal ideation were more common in patients with prurigo 
(37.1%, 29.6% and 19.2%, respectively) than in patients with the 10 other more common 
dermatological diseases (psoriasis, non-melanoma skin cancer, skin infections, eczema, acne, nevi, 
atopic eczema, benign skin tumours, hand eczema, and leg ulcers[AF14]). Studies on the psychological 
consequences of prurigo are scarce. A psychometric study from Dazzi et al. compared 20 patients with 
prurigo nodularis to 20 voluntary subjects (9). Specific questionnaires were used: the General Health 
Questionnaire, State Trait Anxiety Inventory-form Y, Beck Depression Inventory II and Eysenck 
Personality Questionnaire. Symptoms of T-anxiety [AF15]  and depression were significantly more 
common in the group of patients with prurigo than in the control group (51.3% vs 39.5% and 19.2% vs 
7.0%, respectively), but there was no significant difference for S-anxiety. A recent epidemiological 
study based on an analysis of a register included 877 patients with prurigo nodularis and ten times 
more controls (10). The frequencies of anxiety and depression and consumption of anxiolytics and 
antidepressants were significantly higher in patients with prurigo compared to controls, and there was 
no association between prurigo and suicide. Depression was found in 8.5% of patients with prurigo, 
and anxiety was only found in 2.1%. This result could be explained in several ways: the diagnosis was 
probably not always registered in the database, and there was probably an under-diagnosis. Another 
study compared the psychological comorbidities of 94 patients with prurigo not to controls but to 91 
patients with psoriasis (11). There was no significant difference with regard to alexithymia, 
somatization symptoms, hypochondrias, anxiety (present in 18% of patients with prurigo vs. 11% with 
psoriasis) and depression (present in 22% of patients with prurigo and 21% with psoriasis). 
Psychological comorbidities can be considered to be a consequence of prurigo, but depression and 
anxiety can induce psychogenic pruritus and thereby lead to prurigo (12).  
In a previously published study on the same cohort of patients, our patients with prurigo had one of 
the 3 lowest mean EQ-VAS scores (57.4) among the 10 most common dermatological diseases (13). 
This value was similar to that of rheumatoid pain (56.4)(14).  In the linear regression of the EQ-VAS 
score (adjusted for age, sex, socio-economic status and comorbidities), patients with prurigo registered 
the lowest self-reported health (22.3 points lower than controls), after patients with hidradenitis 
suppurativa (24.2), compared to controls (13). Impairment for each of the five dimensions of the EQ5D 
for patients with prurigo compared to controls highlighted an increased odds ratio for all of the 
dimensions: 4.2 [1.7-10.6] for mobility, 7.35 [2.6-21.1] for self-care, 3.26 [1.3-8.2] for activity, 8.63 [2.8-
26.5] for pain/discomfort and 4.90 [1.9-12.4] for depression/anxiety (13). Among the 35 
dermatological diseases studied, for self-care, prurigo was the worst after blistering disease (9.73) [4.4-
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21.6], and for pain/discomfort, prurigo was the worst after hidradenitis suppurativa (50.28) [12.0-
211.0]. 
Among all of the dermatological diseases studied, prurigo had the second worst impact on quality of 
life, with a mean DLQI at 12.4, the same as hidradenitis suppurativa[AF16]. Impairment of quality of life 
is severe: for half of patients, it is considered to be a very or extremely large effect. These data are 
new; in fact, no study has evaluated quality of life in patients with prurigo before (15)[AF17].    
Men were more numerous (59.3%) than women in our group of patients. Prurigo is usually considered 
to be more common in women. In a cohort of 108 prurigo nodularis patients, females represented 
63.9% of the sample (16). Epidemiological data are lacking, so it is difficult to draw conclusions 
concerning the difference between sexes (17). The mean age of patients in our study was 57, and 
pƌuƌigo usuallǇ appeaƌs iŶ ŵiddle age. The ŵeaŶ age ǁas ϲϭ.ϱ Ǉeaƌs iŶ IkiŶg’s studǇ (16). A low level 
of education was significantly more common in patients with prurigo than in controls (60.9% vs 27.8%). 
Some comorbidities were significantly more common in patients with prurigo than in controls: heart 
disease and diabetes. These comorbidities or the drugs used to treat them could be a cause of prurigo. 
There is little information on comorbidities, but diaďetes ǁas pƌeseŶt iŶ ϳ.ϰ% of patieŶts iŶ IkiŶg’s 
cohort (16). 
This study has some limitations. The sample size is limited, but prurigo is a rare disease[AF18].  Prurigo 
was only defined very recently, so there is probably a heterogeneity of diseases named prurigo in our 
study because there was no consensual definition at the time of the study (4). Another limitation is 
that diagnoses of anxiety and depression were made with a questionnaire. Even if the HADS 
questionnaire has been validated[AF19], this method of diagnosis is censurable.  
Prurigo remains relatively unexplored, but researchers are increasingly interested in this disease. In 
particular, the European experts of the Task Force Pruritus published an expert consensus on the 
definition, classification and terminology of chronic prurigo (4). The major criteria are: chronic pruritus 
;≥ϲǁeeksͿ, histoƌǇ aŶd/oƌ sigŶs of ƌepeated sĐƌatĐhiŶg ;e.g., eǆĐoƌiatioŶs aŶd sĐaƌsͿ aŶd loĐalized oƌ 
generalized presence of multiple pruriginous lesions. These lesions occur due to a neuronal 
sensitization to itch and the development of an itch-scratch cycle (4). The treatment of prurigo remains 
challenging because data from randomized controlled trials are sparse (17–20). Some molecules are in 
development, such as neurokinin-1 receptor antagonists or antagonists for IL-31(21).   
This studǇ highlights pƌuƌigo’s sigŶifiĐaŶt iŵpaĐt oŶ ƋualitǇ of life, iŶĐludiŶg the high fƌeƋueŶĐǇ of 
anxiety, depression, and suicidal ideation. Thus, this disease should be further studied to find new 
approaches to management.  
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